DexCom, Inc. $DXCM Shares Sold by Vanguard Personalized Indexing Management LLC

Vanguard Personalized Indexing Management LLC cut its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 16.3% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 37,041 shares of the medical device company’s stock after selling 7,219 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in DexCom were worth $2,493,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in DXCM. Brighton Jones LLC boosted its position in shares of DexCom by 257.7% in the fourth quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock worth $1,290,000 after acquiring an additional 11,946 shares during the last quarter. Integrated Wealth Concepts LLC raised its stake in DexCom by 6.3% during the first quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock worth $227,000 after purchasing an additional 196 shares during the period. Empowered Funds LLC raised its stake in DexCom by 5.4% during the first quarter. Empowered Funds LLC now owns 8,446 shares of the medical device company’s stock worth $577,000 after purchasing an additional 436 shares during the period. Focus Partners Wealth boosted its holdings in shares of DexCom by 13.2% in the 1st quarter. Focus Partners Wealth now owns 7,218 shares of the medical device company’s stock valued at $493,000 after purchasing an additional 841 shares during the last quarter. Finally, GC Wealth Management RIA LLC grew its stake in shares of DexCom by 41.9% during the 2nd quarter. GC Wealth Management RIA LLC now owns 4,155 shares of the medical device company’s stock valued at $363,000 after buying an additional 1,226 shares during the period. 97.75% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on DXCM shares. Wells Fargo & Company set a $93.00 target price on DexCom and gave the stock an “overweight” rating in a research report on Friday, October 31st. TD Cowen cut their price objective on DexCom from $100.00 to $84.00 and set a “buy” rating on the stock in a report on Friday, October 31st. BTIG Research reduced their price objective on DexCom from $109.00 to $85.00 and set a “buy” rating on the stock in a research note on Friday, October 31st. Wall Street Zen downgraded shares of DexCom from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 16th. Finally, Canaccord Genuity Group set a $99.00 price target on shares of DexCom and gave the company a “buy” rating in a report on Friday, October 31st. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, four have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $86.30.

DexCom Stock Up 0.9%

Shares of NASDAQ:DXCM opened at $74.00 on Friday. The company has a market capitalization of $28.86 billion, a price-to-earnings ratio of 41.11, a price-to-earnings-growth ratio of 1.31 and a beta of 1.48. The company has a 50 day moving average of $67.56 and a two-hundred day moving average of $70.95. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $93.25. The company has a quick ratio of 1.38, a current ratio of 1.56 and a debt-to-equity ratio of 0.45.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, October 30th. The medical device company reported $0.61 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.04. The business had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.18 billion. DexCom had a net margin of 15.96% and a return on equity of 30.65%. The business’s revenue for the quarter was up 21.6% compared to the same quarter last year. During the same period in the previous year, the company posted $0.45 earnings per share. As a group, analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insider Buying and Selling

In other DexCom news, Director Richard Alexander Collins sold 2,906 shares of the business’s stock in a transaction on Friday, November 14th. The shares were sold at an average price of $59.05, for a total value of $171,599.30. Following the transaction, the director owned 35,088 shares in the company, valued at $2,071,946.40. The trade was a 7.65% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Bridgette P. Heller sold 1,012 shares of the firm’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $58.07, for a total value of $58,766.84. Following the sale, the director owned 27,031 shares of the company’s stock, valued at $1,569,690.17. This represents a 3.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 7,866 shares of company stock valued at $448,177 in the last quarter. Company insiders own 0.32% of the company’s stock.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.